Recombinant Gallid herpesvirus 3 (MDV serotype 2) vectors expressing antigens of avian pathogens and uses thereof
The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.
1. A vaccine composition comprising:
1) a recombinant Gallid herpesvirus 3 (MDV-2) strain SB-1 vector, wherein said vector comprises a heterologous polynucleotide coding for and expressing in vivo, a Newcastle Disease Virus (NDV) Fusion protein (NDV-F), and
2) a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant;
wherein the NDV-F protein has at least 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2 or wherein the NDV-F protein comprises SEQ ID NO:9.
2. A vaccine composition comprising:
1) a recombinant Gallid herpesvirus 3 (MDV-2) strain SB-1 vector, wherein said vector comprises a heterologous polynucleotide coding for and expressing in vivo, an NDV Fusion protein (NDV-F),
2) a recombinant Herpesvirus of Turkeys (HVT) vector, wherein HVT is also known as MDV-3 or Meleagrid herpesvirus 1, wherein the vector comprises a heterologous polynucleotide coding for and expressing in vivo, an Infectious bursal disease virus (IBDV) VP2, and
3) a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant.
3. The vaccine composition of claim 1 or 2 , wherein the heterologous polynucleotide coding for NDV-F is inserted into the region between ORF UL55 and ORF LORF5 in the unique long (UL) region of the recombinant MDV-2 strain SB-1 vector.
4. The vaccine composition of claim 1 or 2 , wherein the recombinant MDV-2 strain SB-1 vector comprises a heterologous promoter, and expression of NDV-F is under the control of said promoter, wherein said promoter is selected from an immediate early CMV promoter, a mouse CMV promoter, a guinea pig CMV promoter, an SV40 promoter, a Pseudorabies Virus glycoprotein X promoter, a Herpes Simplex Virus-1 alpha 4 promoter, a Marek's Disease Virus glycoprotein C promoter, a Marek's Disease Virus glycoprotein B promoter, a Marek's Disease Virus glycoprotein E promoter, an Infectious Laryngotracheitis Virus glycoprotein B, an Infectious Laryngotracheitis Virus glycoprotein E promoter, an Infectious Laryngotracheitis Virus glycoprotein D promoter, an Infectious Laryngotracheitis Virus glycoprotein I promoter, or a Bovine Herpesvirus 1.1 VP8 promoter.
5. The vaccine composition of claim 2 , wherein the NDV-F protein has at least 95% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NOs: 2, 5, 7, or 9.
6. The vaccine composition of claim 2 , wherein the polynucleotide encoding NDV-F has at least 95% sequence identity to SEQ ID NO: 1, 3, 4, 6, or 8.
7. The vaccine composition of claim 4 , wherein the heterologous promoter comprises a mouse CMV promoter, a SV40 promoter, or a guinea pig CMV promoter.
8. The vaccine composition of claim 1 or 2 , wherein the heterologous polynucleotide coding for NDV-F is in the region between ORF SORF4 and ORF US10 of the recombinant MDV-2 strain SB-1 vector.
9. The vaccine composition of claim 1 or 2 , wherein heterologous polynucleotide coding for NDV-F is in the region between ORF SORF4 and ORF US2 of the recombinant MDV-2 strain SB-1 vector.
10. The vaccine composition of claim 1 or 2 , wherein heterologous polynucleotide coding for NDV-F is in the region coding for glycoprotein C (UL44) of the recombinant MDV-2 strain SB-1 vector.